September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
Current Advances in Continuous Glucose Monitoring Technology
CGMs have revolutionized diabetes management for patients and healthcare providers alike. This slide show summarizes the most recent enhancements.
Continuous Glucose Monitoring for Type 2 Diabetes in Primary Care: 2021 Research Review
Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.
Finerenone Reduces Risk of Incident HF in Patients with T2D + CKD in FIGARO-DKD Analyses
Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.
Obesity Linked to Elevated Risk of Heart Failure in Persons with Diabetes
Increases in obesity parameters significantly increased risk of incident heart failure in persons with diabetes, but not without diabetes, in a large community-based cohort study.
DIABETES: 2021 Clinical Focus Collection
ADA 2021 Scientific Sessions recap, tests of clinical knowledge, expert interviews, and more in this roundup from Patient Care Online.
In Adults with T2D, Low-energy Diets with Meal Replacement Most Effective for Weight Loss, Remission
Weight loss and disease remission in T2D may differ between patients regardless of type of diet regimen chosen, say authors of a new analysis.
Canagliflozin Improved HF Symptoms, QOL Regardless of Diabetes Status in Fully Remote Clinical Trial
AHA 2021. Heart failure patients, across ejection fraction and diabetes status, reported improved QOL as early as 3 months in CHIEF-HF trial.
Finerenone Slows CKD Progression Across Disease Spectrum, According to New Analysis
Finerenone was associated with a 20% lower risk of end-stage kidney disease among patients with T2D and CKD, according to authors of the FIDELITY analysis.
Cardiovascular Risk Found Greatest in Prediabetes A1c Range
For individuals with A1c of 6.4-6.5%, just below the threshold for diabetes, risk of MACE was higher than for any other subgroup with A1c values ranging from 5.8-6.8%.
COVID-19 Lockdown Had Significant, Yet Varying, Impact on Glycemic Control
EASD 2021: First analysis of its kind found COVID-19-induced lockdown was associated with improved glycemic control among patients with T1D, but not T2D.
SUSTAIN-10 Post-hoc Analysis Suggests Additive Benefits for GLP-1 RA-SGLT-2i Combination
This post-hoc analysis showed increased reductions in A1c, weight, and BP in T2D patients prescribed GLP-1 receptor agonists who were already taking an SGLT-2 inhibitor.
Reverse-dipping BP, Heart Rate Variability Linked to Increased All-cause Mortality in Diabetes
A pattern of nocturnal reverse-dipping blood pressure in persons with type 1 or 2 diabetes put them at more than twice the risk of all-cause mortality, according to new research.
Sustained Weight Loss May Reverse CV Risk Factors Linked to Obesity, Study Shows
EASD 2021: For persons who have had obesity, returning to a healthy weight may reduce risk for hypertension and dyslipidemia, and modestly for diabetes.
Women with T2D Less Likely to Receive Guideline-recommended Cardiovascular Care vs Men
EASD 2021: Women with type 2 diabetes were less likely to meet targets for CV risk management vs men but at lower risk for future CV events, a new study found.
Prevalence of Type 1 and Type 2 Diabetes “Surging” among US Youth, Shows New Study
From 2001 to 2017, the estimated prevalence of youth-onset T1D and T2D increased approximately 45% and 95%, respectively, according to a new study.
ESC 2021: Finerenone Now Shows Promise in Less Severe Diabetic Kidney Disease
Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.
European Society of Cardiology Congress 2021: Primary Care Preview
The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.
USPSTF Lowers Age to Begin Screening for Diabetes, Prediabetes
Citing data that show the incidence of type 2 diabetes increases at age 35 years, the Task Force now recommends the younger age to initiate screening vs the current age of 40 years.
FDA Grants Insulin Lispro-aabc Label Expansion for use in Insulin Pumps
The novel prandial insulin formulation from Eli Lilly is now approved for administration via continuous subcutaneous insulin infusion with an insulin pump.
Empagliflozin FDA-approved for Heart Failure with Reduced Ejection Fraction
The new indication for empagliflozin is to reduce risk of CV death and hospitalization for heart failure in patients with HFrEF,
High-deductible Health Plans May Negatively Impact Patients with Diabetes, New Review Suggests
Low-income patients with diabetes enrolled in high-deductible health plans used less preventive and primary care services and more emergency visits, suggests new review.
8 Questions on Diabetes Drugs for Cardioprotection
Take this quick quiz to test your knowledge of key findings in landmark studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.
Diabetes Drugs and Cardioprotection: A Summary for Primary Care
These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.
In Patients with Uncontrolled T2D, Bariatric Surgery Associated with Long-term Improvement in Physical Domains, Diabetes-related QoL
Five years after bariatric surgery for uncontrolled T2D patients reported improvements in physical health and QoL but measures of psychosocial wellbeing remained flat.
Improved Outcomes Seen with Regular Antidepressant Use in Patients with Diabetes and Depression
Antidepressant therapy, used as prescribed, reduced risk for advanced complications of diabetes and death among more than 36 000 patients with comorbid diabetes and depression.
Achieving A1c Levels Below 7% Early May be Predictive of Long-term Glycemic Control in Patients with T2D
Early attainment of an A1c level below 7% was predictive of long-term glycemic control in patients with type 2 diabetes starting second-line glucose-lowering therapy in a new analysis.
Finerenone Approved as First-in-Class Treatment for Chronic Kidney Disease Associated with Type 2 Diabetes
The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.
Study: Statins Reduce CVD, Mortality in Low-risk Patients with Type 2 Diabetes
A recent study found that the use of statins in patients with newly diagnosed T2D reduced incidence of cardiovascular disease and death, particularly among older patients.
SGLT2 Inhibitors: 4 Questions Go Back to Basics
The SGLT-2 inhibitor class, originally approved as antihyperglycemic agents for T2D, has proven "pluripotent," adding indications for related conditions. Test your knowledge of a few basic facts.
At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors
Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.